U.S. Markets closed

Biogen halts trial of its Alzheimer’s drug Aducanumab

Biogen decided to end its phase 3 trial of its Alzheimer’s drug Aducanumab. Heritage Capital LLC President Paul Schatz and Yahoo Finance’s Brian Sozzi, Scott Gamm and Alexis Christoforous break down the impact on the company.